Compare · NVO vs THAR
NVO vs THAR
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tharimmune Inc. (THAR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and THAR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, NVO is down 34.2% and THAR is up 248.9% - THAR leads by 283.1 points.
- NVO has hit the wire 5 times in the past 4 weeks while THAR has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for THAR).
- Company
- Novo Nordisk A/S
- Tharimmune Inc.
- Price
- $41.18+6.93%
- $4.75+6.03%
- Market cap
- $220.35B
- -
- 1M return
- +13.32%
- +58.70%
- 1Y return
- -34.24%
- +248.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest THAR
- Tharimmune Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
- SEC Form 3 filed by new insider Radkowski Angela Dominy
- SEC Form 3 filed by new insider Sommers Jill E.
- SEC Form 3 filed by new insider Wiley William Thomas Jr.
- SEC Form 3 filed by new insider Asbury Jacob
- SEC Form SCHEDULE 13G filed by Tharimmune Inc.
- Tharimmune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
- SEC Form SCHEDULE 13G filed by Tharimmune Inc.